Seattle Genetics (SGEN) Tops Q4 EPS by 2c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/4/2026
- Equities close higher as softer jobs data quiets rate-hike expectations
- U.S. economy adds fewer jobs than expected as unemployment rate ticks higher
- Nvidia returns as Morgan Stanley’s Top Pick on attractive valuation
- Citi says rate volatility without Fed repricing is concerning
- U.S. credit-reporting stocks fall as FHFA weighs two-bureau mortgage rule
- Equities close higher as softer jobs data quiets rate-hike expectations
- Cantor Fitzgerald on Rivian (RIVN): 'pre-announced that it delivered 19,248 vehicles in 3Q26, above our estimate'
- DISH DBS emerges from bankruptcy, cuts debt by $4.35 billion
- Tanker struck by projectile in Strait of Hormuz
- AppLovin shares fall after court denies request against Unity
Seattle Genetics Reports Fourth Quarter and Year 2015 Financial Results
February 9, 2016 4:02 PM EST-Total 2015 Revenues of $336.8 Million, Including $226.1 Million in ADCETRIS® (Brentuximab Vedotin) U.S. and Canada Net Product Sales-
-Total 2016 Revenues Expected to Increase to a Range of $390 Million to $430 Million, Including ADCETRIS U.S. and Canada Net Sales of $255 Million to $275 Million-
-Vadastuximab Talirine (SGN-CD33A) Phase 3 Trial Initiation Planned by Third Quarter of 2016-
-Data from ADCETRIS Phase 3 ALCANZA Trial Expected in Second Half of 2016-
-Conference Call Today at 4:30 p.m. ET-
BOTHELL, Wash.--(BUSINESS WIRE)--... More
